Response to &quot;Letermovir prophylaxis and CMV immune monitoring: Toward a win-win strategy in heart transplantation&quot;.

Prevymis (letermovir) - Merck (MSD)

Response to "Letermovir prophylaxis and CMV immune monitoring: Toward a win-win strategy in heart transplantation". (PubMed, J Heart Lung Transplant) - Nov 7, 2025 - No abstract available
Journal • Transplantation

http://www.ncbi.nlm.nih.gov/pubmed/41201428

David R Snydman; Jennifer K L Chow

Nov 7, 2025